Jade Biosciences (NASDAQ:JBIO) Upgraded by Lifesci Capital to “Strong-Buy” Rating

Jade Biosciences (NASDAQ:JBIO) was upgraded by investment analysts at Lifesci Capital to a “strong-buy” rating in a report issued on Friday,Zacks.com reports.

A number of other brokerages have also commented on JBIO. HC Wainwright assumed coverage on shares of Jade Biosciences in a research report on Wednesday, January 7th. They set a “buy” rating and a $25.00 target price on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jade Biosciences in a report on Monday, December 29th. Stifel Nicolaus set a $40.00 price objective on Jade Biosciences in a research note on Friday. Guggenheim lifted their target price on Jade Biosciences from $14.00 to $17.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. Finally, Wall Street Zen upgraded Jade Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $24.00.

Jade Biosciences Trading Up 1.2%

Shares of JBIO opened at $14.05 on Friday. The firm has a fifty day moving average price of $14.78 and a 200-day moving average price of $11.89. The firm has a market capitalization of $692.81 million, a P/E ratio of -1.26 and a beta of 1.03. Jade Biosciences has a 12-month low of $6.57 and a 12-month high of $100.10.

Jade Biosciences (NASDAQ:JBIO) last posted its quarterly earnings results on Friday, March 6th. The company reported ($0.11) EPS for the quarter.

Institutional Investors Weigh In On Jade Biosciences

A number of large investors have recently bought and sold shares of JBIO. RA Capital Management L.P. lifted its position in Jade Biosciences by 245.6% during the fourth quarter. RA Capital Management L.P. now owns 3,671,083 shares of the company’s stock valued at $56,645,000 after purchasing an additional 2,608,757 shares during the period. Frazier Life Sciences Management L.P. purchased a new stake in shares of Jade Biosciences during the second quarter worth approximately $17,703,000. Baker BROS. Advisors LP acquired a new position in Jade Biosciences during the fourth quarter worth about $25,323,000. Remedium Capital Partners LLC purchased a new position in Jade Biosciences during the fourth quarter worth approximately $24,345,000. Finally, Versant Venture Management LLC purchased a new stake in shares of Jade Biosciences in the second quarter valued at about $15,243,000.

Jade Biosciences Company Profile

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.